Luminex Corporation We would like to show you a description here but the site won’t allow us
Luminexs Inbound Marketing Blog This blog is not the place for specific performance characterstics of diagnostics products or to report problems with any Luminex products Problems should be submitted to our support group at support@luminexcorp com
Luminex Submits Joint SARS-CoV-2 and Flu RSV Respiratory Panel to FDA . . . AUSTIN, Texas, March 10, 2021 PRNewswire -- Luminex Corporation (NASDAQ: LMNX) today announced that it has submitted an Emergency Use Authorization application to the U S Food and Drug Administration for the company's new multi-analyte respiratory panel combining Flu A B and respiratory syncytial virus (RSV) targets with the SARS-CoV-2 target
Luminex MAGPIX System Shown to be More Cost Effective and Efficient . . . Luminex Corporation (Nasdaq: LMNX), today announced that initial results from a study conducted at the NMI Natural and Medical Sciences Institute at the University of Tubingen in Germany demonstrate that its MAGPIX(R) system provides more cost effective and efficient results than a conventional microtiter plate based ELISA method
Charles Collins, Ph. D. | Management | Luminex Corporation Dr Collins joined Luminex Corporation in 2006 and was named Vice President of Systems Research and Development in May 2012 During his tenure Dr Collins has held increasing leadership positions most recently as Senior Director of the Advanced Technology Group